Altevax

Altevax is a French clinical-stage biotechnology company pioneering the development of innovative cancer immunotherapies. The company's proprietary platform utilizes synthetic melanin as an adjuvant combined with disease-specific peptides to trigger a highly potent, antigen-specific T-cell immune response. Altevax's lead program, MELITECH (NAVIG-1 vaccine), is currently in a Phase 1/2a clinical trial (NAVIG-1) for the treatment of newly diagnosed glioblastoma, targeting telomerase (TERT) and PTPRZ1. By mimicking a physiological immune response, Altevax aims to deliver highly specific, effective, and well-tolerated treatments for aggressive cancers and infectious diseases.